Who is sponsoring NCT07523516?

NCT07523516 is sponsored by Assiut University.

What condition does NCT07523516 study?

NCT07523516 studies Breast Cancer (Locally Advanced or Metastatic).

Is NCT07523516 still recruiting?

NCT07523516 is currently not yet recruiting. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07523516

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Performance of 18F-FDG PET/CT in Detecting Distant Metastases in Breast Cancer

Not yet recruiting Last updated 13 April 2026

What this trial tests

trial in Breast Cancer (Locally Advanced or Metastatic) in 97 participants. Not yet recruiting.

Timeline

1 April 2026

Primary endpoint
1 April 2026

1 April 2029

Quick facts

Lead sponsor	Assiut University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	97
Start date	1 April 2026
Primary completion	1 April 2026
Estimated completion	1 April 2029

Conditions studied

Breast Cancer (Locally Advanced or Metastatic) — all drugs for Breast Cancer (Locally Advanced or Metastatic) →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Breast Cancer (Locally Advanced or Metastatic). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

compare the accuracy and sensitivity of 18F FDG-PET/CT and CE-CT in detecting distant metastases in breast cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer (Locally Advanced or Metastatic)

Currently open trials in the same condition.

NCT07457541 — Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI · Phase 1 · active not recruiting
NCT07486089 — Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) · Phase 1, PHASE2 · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07478900 — Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer · NA · recruiting
NCT07390838 — A Study of SH009 Injection in Patients With Advanced Solid Tumors. · Phase 1 · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07523516 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07523516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing